Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Tull

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical Medicine (London, England)|May 18, 2021
Immunobullous diseaseThomas J Tull, Emma Benton
The British Journal of Dermatology|May 20, 2025
A current need for the use of improved and standardized outcome measures by clinical studies of pemphigusThomas J Tull, Jane Setterfield
The British Journal of Dermatology|April 12, 2026
Low dose methotrexate and superpotent topical steroids in the management of bullous pemphigoidLucy Mackie, Thomas J Tull
Clinical and Experimental Immunology|January 8, 2023
Human B-cell subset identification and changes in inflammatory diseasesRebekah L Velounias, Thomas J Tull
Clinical and Experimental Immunology|December 13, 2022
Human B cellsJo Spencer, Mats Bemark, Thomas J Tull
Immunology Letters|April 11, 2023
Weller et al., T-independent responses to polysaccharides in humans mobilize marginal zone B cells pre-diversified against gut bacterial antigensJo Spencer, Thomas J Tull, Mats Bemark
British Journal of Hospital Medicine (London, England : 2005)|November 10, 2015
Cutaneous lupus erythematosusThomas J Tull, Andrew E Pink, Emma C Benton, et al.
Clinical and Experimental Dermatology|October 10, 2024
Efficacy of rituximab in the treatment of epidermolysis bullosa acquisitaSosipatros P Bratsos, Zilan Demir, John B Mee, et al.
Clinical and Experimental Dermatology|December 13, 2024
A widespread chronic pruritic varioliform ulcerating eruptionConn McGrath, Thomas J Tull, Dorota Markiewicz, et al.
Oncoimmunology|March 7, 2026
B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapyLucy Booth, Madeena Mahmood, Xinyi Chen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Medicine (London, England)|May 18, 2021
Immunobullous diseaseThomas J Tull, Emma Benton
The British Journal of Dermatology|May 20, 2025
A current need for the use of improved and standardized outcome measures by clinical studies of pemphigusThomas J Tull, Jane Setterfield
The British Journal of Dermatology|April 12, 2026
Low dose methotrexate and superpotent topical steroids in the management of bullous pemphigoidLucy Mackie, Thomas J Tull
Clinical and Experimental Immunology|January 8, 2023
Human B-cell subset identification and changes in inflammatory diseasesRebekah L Velounias, Thomas J Tull
Clinical and Experimental Immunology|December 13, 2022
Human B cellsJo Spencer, Mats Bemark, Thomas J Tull
Immunology Letters|April 11, 2023
Weller et al., T-independent responses to polysaccharides in humans mobilize marginal zone B cells pre-diversified against gut bacterial antigensJo Spencer, Thomas J Tull, Mats Bemark
British Journal of Hospital Medicine (London, England : 2005)|November 10, 2015
Cutaneous lupus erythematosusThomas J Tull, Andrew E Pink, Emma C Benton, et al.
Clinical and Experimental Dermatology|October 10, 2024
Efficacy of rituximab in the treatment of epidermolysis bullosa acquisitaSosipatros P Bratsos, Zilan Demir, John B Mee, et al.
Clinical and Experimental Dermatology|December 13, 2024
A widespread chronic pruritic varioliform ulcerating eruptionConn McGrath, Thomas J Tull, Dorota Markiewicz, et al.
Oncoimmunology|March 7, 2026
B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapyLucy Booth, Madeena Mahmood, Xinyi Chen, et al.
Pageof 3